A **VISION** for

HCV *free* country by 2030



2030

A **VISION** for

HCV *free* **country** by **2030**

Guidance to simplified treatment & pre-treatment assessment

HEPC-SA-00001-MC

Pre-treatment Assessment

I. **Cirrhosis assessment:**
A patient is presumed to have cirrhosis if they have :

- FIB-4 score >3.25
- Transient elastography (eg, FibroScan stiffness >12.5 kPa)
- APRI score > 1
- Clinical evidence of cirrhosis (e.g, liver nodularity and/or splenomegaly on imaging, platelet count <150,000/mm3, etc)
- Prior liver biopsy showing cirrhosis

Pre-treatment Assessment

II. Complete blood count (CBC)

III. Hepatic function panel (ie, albumin, total and direct bilirubin, alanine aminotransferase [ALT], aspartate aminotransferase [AST])

IV. Urine analysis & Calculated glomerular filtration rate (eGFR)

V. Quantitative HCV RNA (HCV viral load)

VI. HIV antigen/antibody test

VII. Hepatitis B surface antigen

VIII. Serum pregnancy testing and counseling about pregnancy risks of HCV medication should be offered to women of childbearing age.

Simplified HCV treatment

Who is eligible for simplified treatment

Adults with chronic hepatitis C (any genotype) who do not have cirrhosis and have not previously received hepatitis C treatment

Who is NOT eligible for simplified treatment

Patients who have any of the following characteristics:

- Prior hepatitis C treatment
- Cirrhosis HIV or HBsAg positive
- Current pregnancy
- Prior liver transplantation or signs of HCC
- Any of the referral criteria as per previous guidance

Simplified treatment options

HCV treatment options from 2017 & forward

Treatment is now simpler

2017

Short
8 -12 weeks

Pan-genotypic
Covering all HCV genotypes

Tolerable
Minimal monitoring

Simple
Minimal pre-testing required

Resources

- For more data about HCV treatment regimens, please refer to hepatologists or primary health care doctors in this list who involved in Saudi HCV national elimination program (link to Primary health care list)
- Kindly find the below links for simplified treatment guidance from American association for study of liver disease (AASLD)
  Link for non cirrhotic patients
  Link for compensated cirrhotic patients

References

- Recommendations for Testing, Managing, and Treating Hepatitis C / AASLD 2019 guidelines| HCV Guidance /Hcvguidelines.org. 2020 [cited 15 September 2020].

A vision towards Saudi Arabia free of HCV by 2030

The 1st country to achieve HCV elimination in Asia

www.HepC2030-sa.com